A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

Exclusion Criteria

• •Malignancy within the past 2 years.
• •Patients who have undergone neurolytic or neurosurgical therapy for postherpetic neuralgia.
• •Creatinine clearance \</= 30 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).
• •Patients having other severe pain which may impair the self assessment of the pain due to postherpetic neuralgia.
• •Skin conditions in the affected dermatome that could alter sensation.